18Oct 2023
Vesical Imaging System Predicts Pembrolizumab Outcome in Bladder Cancer

Vesical Imaging System Predicts Pembrolizumab Outcome in Bladder Cancer

In the PURE-01 trial, researchers assessed the effectiveness of pre- and post-pembrolizumab Vesical Imaging-Reporting and Data System (VI-RADS) in predicting responses in muscle-invasive bladder cancer. Results from 110 patients who underwent centrally reviewed scans between February 2017 and July 2020 revealed that both pre- and post-pembrolizumab VI-RADS scores between 0-3 significantly predicted the ypT≤1N0 endpoint. Post-pembrolizumab VI-RADS 0-3 also correlated with improved event-free survival and overall survival. The study emphasized the potential of VI-RADS as a crucial component for future research and trials focusing on muscle-invasive bladder cancer.

  • #urology

Like

Save

Share